VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study
Nov 30, 20157:00 AM
VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles
Nov 19, 20157:00 AM
VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy
Nov 17, 20159:00 AM
VolitionRx Granted Its Second U.S. Patent
Nov 12, 20157:00 AM
VolitionRx to Present at Two Conferences in November
Nov 04, 20156:30 AM
VolitionRx Announces Third Quarter 2015 Financial Results and Business Update
Oct 30, 20157:00 AM
VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET
Oct 22, 20158:00 AM
VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study
Oct 12, 20158:00 AM
VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics
Sep 22, 20158:00 AM
VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer
Sep 10, 20158:00 AM
VolitionRx Granted Its First U.S. Patent
Sep 09, 20159:00 AM
VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial
Sep 02, 20159:00 AM
VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015
Sep 01, 20159:00 AM
VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015
Aug 17, 20159:00 AM
VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer
Aug 11, 20157:30 AM
VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
Aug 05, 20159:00 AM
VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET
Aug 03, 20159:00 AM
VolitionRx to Present at Wedbush PacGrow Healthcare Conference
Jul 27, 20159:00 AM
VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs
Jul 08, 20159:00 AM
VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar
Jul 06, 20159:18 AM
VolitionRx Expands Scientific Advisory Board
Jun 23, 20159:00 AM
VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe
May 19, 20159:00 AM
VolitionRx to Present at Two Upcoming Investor Conferences
May 18, 20159:00 AM
VolitionRx CEO Cameron Reynolds to Present Informational Webinar
May 12, 20158:50 AM
VolitionRx Announces First Quarter 2015 Financial Results and Business Update
May 08, 20159:00 AM
VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers
May 06, 20159:00 AM
VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET
Apr 21, 20159:00 AM
VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps
Apr 09, 20159:00 AM
VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials
Mar 05, 20158:00 AM
VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology
Feb 24, 20158:00 AM
VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent
Feb 17, 20158:00 AM
VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering
Feb 06, 20158:00 AM
VolitionRx Limited Prices Public Offering of Common Stock
Jan 20, 20155:00 PM
VolitionRx Begins First Ovarian Cancer Detection Study
Jan 07, 20158:00 AM
Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers